Current Edition

Lymphoma

Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analyst

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …

Continue Reading →